FDA approves changes to Byetta label

11/2/2009 | Reuters · Wall Street Journal, The

The FDA approved a revised label for diabetes drug Byetta to include reports of problems with kidney function. The decision came days after Eli Lilly and Co. and Amylin Pharmaceuticals received clearance to promote Byetta as a stand-alone treatment for Type 2 diabetes.

View Full Article in:

Reuters · Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Executive Officer
CarePoint Health Plan
Jersey City, NJ
Regional Director, Southeastern Region - State Affairs
America's Heatlh Insurance Plans (AHIP)
Washington, DC
Assistant General Counsel
Cardinal Health
Columbus, OH
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC